Can a smart monitor prevent dangerous drops in blood pressure during oral cancer surgery?
NCT ID NCT07405892
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will test whether a device called the Hypotension Prediction Index (HPI) can help doctors keep blood pressure stable during oral cancer surgery. About 100 adults having oral cancer surgery with flap reconstruction will take part. Half of the surgeries will use the HPI device to guide care, while the other half will not. The goal is to see if using the device reduces the severity and duration of low blood pressure and leads to fewer major complications after surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Hypotension Prediction Index (HPI) software used with a standard monitor
- What this could lead to
- If it works, this could point toward a way to reduce serious complications after oral cancer surgery by better managing blood pressure during the operation.
- What could go wrong
- This is a small, early-stage study that hasn't started recruiting yet. The device may not meaningfully improve outcomes, and results may not apply to other types of surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ORAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a glowing drug light up head and neck tumors?
- Can a single tracer light up cancer's first stop? a trial puts a hybrid dye-and-radioactive marker to the test.
- New tracheostomy tube holder aims to cut infections and boost comfort
- HIV and cancer: study seeks to uncover hidden risk factors
- New drug combo targets HPV-Driven cancers in phase II trial
- Could an immunotherapy combo replace harsh chemo for head and neck cancer?